The effect of caffeine on glucose kinetics in humans influence of adrenaline

被引:27
作者
Battram, DS [1 ]
Graham, TE
Richter, EA
Dela, F
机构
[1] Univ Guelph, Dept Human Hlth & Nutr Sci, Guelph, ON N1G 2W1, Canada
[2] Univ Copenhagen, Copenhagen Muscle Res Ctr, Inst Exercise & Sport Sci, Copenhagen, Denmark
[3] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark
来源
JOURNAL OF PHYSIOLOGY-LONDON | 2005年 / 569卷 / 01期
关键词
D O I
10.1113/jphysiol.2005.097444
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
While caffeine impedes insulin-mediated glucose disposal in humans, its effect on endogenous glucose production (EGP) remains unknown. In addition, the mechanism involved in these effects is unclear, but may be due to the accompanying increase in adrenaline concentration. We studied the effect of caffeine on EGP and glucose infusion rates (GIR), and whether or not adrenaline can account for all of caffeine's effects. Subjects completed three isoglycaemic-hyperinsulinaemic clamps (with 3-[H-3] glucose infusion) 30 min after ingesting: (1) placebo capsules (n = 12); (2) caffeine capsules (5 mg kg(-1)) (n = 12); and either (3) placebo plus a high-dose adrenaline infusion (HAdr; adrenaline concentration, 1.2 nm; n = 8) or (4) placebo plus a low-dose adrenaline infusion (LAdr; adrenaline concentration, 0.75 nm; n = 6). With caffeine, adrenaline increased to 0.6 nm but no effect on EGP was observed. While caffeine and HAdr decreased GIR by 13 (P < 0.05) and 34% (P < 0.05) versus the placebo, respectively, LAdr did not result in a significant reduction (5%) in GIR versus the placebo. Due to the fact that both caffeine and LAdr resulted in similar adrenaline concentrations, but resulted in different decreases in GIR, it is concluded that adrenaline alone does not account for the effects of caffeine and additional mechanisms must be involved.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 37 条
[21]   Caffeine can decrease insulin sensitivity in humans [J].
Keijzers, GB ;
De Galan, BE ;
Tack, CJ ;
Smits, P .
DIABETES CARE, 2002, 25 (02) :364-369
[22]   Fatty acid-induced insulin resistance: Decreased muscle PI3K activation but unchanged Akt phosphorylation [J].
Kruszynska, YT ;
Worrall, DS ;
Ofrecio, J ;
Frias, JP ;
Macaraeg, G ;
Olefsky, JM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :226-234
[23]   STUDIES ON THE INSULIN-ANTAGONISTIC EFFECT OF CATECHOLAMINES IN NORMAL MAN - EVIDENCE FOR THE IMPORTANCE OF BETA-2-RECEPTORS [J].
LAGER, I ;
ATTVALL, S ;
ERIKSSON, BM ;
VONSCHENK, H ;
SMITH, U .
DIABETOLOGIA, 1986, 29 (07) :409-416
[24]   Effect of epinephrine on muscle glycogenolysis and insulin-stimulated muscle glycogen synthesis in humans [J].
Laurent, D ;
Petersen, KF ;
Russell, RR ;
Cline, GW ;
Shulman, GI .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1998, 274 (01) :E130-E138
[25]   Caffeine ingestion is associated with reductions in glucose uptake independent of obesity and type 2 diabetes before and after exercise training [J].
Lee, S ;
Hudson, R ;
Kilpatrick, K ;
Graham, TE ;
Ross, R .
DIABETES CARE, 2005, 28 (03) :566-572
[26]   CATECHOLAMINE AND GUANINE-NUCLEOTIDE ACTIVATION OF SKELETAL-MUSCLE ADENYLATE-CYCLASE [J].
NAMBI, P ;
DRUMMOND, GI .
BIOCHIMICA ET BIOPHYSICA ACTA, 1979, 583 (03) :287-294
[27]   Portal vein caffeine infusion enhances net hepatic glucose uptake during a glucose load in conscious dogs [J].
Pencek, RR ;
Battram, D ;
Shearer, J ;
James, FD ;
Lacy, DB ;
Jabbour, K ;
Williams, PE ;
Graham, TE ;
Wasserman, DH .
JOURNAL OF NUTRITION, 2004, 134 (11) :3042-3046
[28]   MECHANISMS LIMITING GLYCOGEN-STORAGE IN MUSCLE DURING PROLONGED INSULIN STIMULATION [J].
RICHTER, EA ;
HANSEN, SA ;
HANSEN, BF .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 255 (05) :E621-E628
[29]   ROLE OF GLUCONEOGENESIS IN EPINEPHRINE-STIMULATED HEPATIC GLUCOSE-PRODUCTION IN HUMANS [J].
SACCA, L ;
VIGORITO, C ;
CICALA, M ;
CORSO, G ;
SHERWIN, RS .
AMERICAN JOURNAL OF PHYSIOLOGY, 1983, 245 (03) :E294-E302
[30]   CAFFEINE AND THEOPHYLLINE ATTENUATE ADENOSINE-INDUCED VASODILATION IN HUMANS [J].
SMITS, P ;
LENDERS, JWM ;
THIEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (04) :410-418